1. Early changes in waivered clinicians and utilization of buprenorphine for opioid use disorder after implementation of the 2021 HHS Buprenorphine Practice Guidelines Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, December 2, 2022 Subject(s): Buprenorphine -- therapeutic useDrug Prescriptions -- statistics & numerical dataDrug Utilization -- statistics & numerical dataDrug Utilization -- trendsOpioid-Related Disorders -- drug therapyPractice Guidelines as TopicScope of PracticeUnited StatesUnited States. Department of Health and Human Services.
